Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients

PHASE3TerminatedINTERVENTIONAL
Enrollment

724

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

October 10, 2017

Study Completion Date

May 31, 2018

Conditions
Clear Cell Renal Carcinoma
Interventions
DRUG

Axitinib

Axitinib 5 mg twice daily

DRUG

Placebo

Placebo twice daily

Trial Locations (106)

10467

New York

12208

Albany

20007

Washington D.C.

21403

Annapolis

23502

Norfolk

29412

Charleston

30322

Atlanta

34471

Ocala

37421

Chattanooga

55118

Saint Paul

68198

Omaha

75203

Dallas

76022

Bedford

77024

Houston

78217

San Antonio

78234

San Antonio

78731

Austin

80218

Denver

90033

Los Angeles

92093

La Jolla

94304

Palo Alto

94523

Pleasant Hill

95109

Seattle

97227

Portland

21231-1000

Baltimore

07601

Hackensack

Unknown

Beijing

Changchun

Chongqing

Dalian

Guangzhou

Hangzhou

Jinan

Nanchang

Shanghai

Suzhou

Tianjin

Wuhan

Besançon

Bordeaux

Hyères

Le Mans

Lyon

Marseille

Paris

Rennes

Saint-Herblain

Suresnes

Vandœuvre-lès-Nancy

Hong Kong

Ahmeadbad

Aurangabad

Bangalore

Chennai

Hyderabad

Karamsad

Kochi

Kolkota

Lucknow

Ludhiana

Mangalore

Manipal

Mumbai

Nashik

New Delhi

Pune

Surat

Visakhapatnam

Aichi

Akita

Aomori

Chiba

Fukuoka

Gifu

Hokkaido

Hyōgo

Kagawa

Kanagawa

Kumamoto

Kyoto

Nagasaki

Nigata-honmachi

Osaka

Shizuoka

Tokushima

Tokyo

Yamagata

Yamaguchi

Busan

Daegu

Daejeon

Gyeonggi-do

Jeonnam

Seoul

Barcelona

Donostia / San Sebastian

Leganés

Llobregat

Madrid

Oviedo

Seville

Valencia

Zaragoza

Taichung

Taipei

Taoyuan District

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

collaborator

SFJ Pharmaceuticals, Inc.

INDUSTRY

lead

SFJ Pharma Ltd. II

INDUSTRY

NCT01599754 - Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients | Biotech Hunter | Biotech Hunter